Literature DB >> 23797180

Fat necrosis of the breast in the accelerated partial breast irradiation era: the need for a universal grading system.

Andrea L Russo1, Alphonse G Taghian.   

Abstract

Fat necrosis of the breast is increasingly reported and used as a trial endpoint in the treatment of breast cancer with accelerated partial breast irradiation (APBI). Yet, there is no universal toxicity scoring system within the latest version of the Common Terminology Criteria for Adverse Events (CTCAE v4.0). This requires investigators to adopt their own scoring system or improperly use those that exist, and limits accurate reporting of this entity. Fat necrosis of the breast also creates diagnostic uncertainty among clinicians and concern of recurrence among patients. In this review, we address the question of increasing incidence of fat necrosis through the comparison of recent APBI trials and literature. The pathogenesis, symptoms, clinical and radiologic diagnosis, clinical predictors of developing fat necrosis, management and follow-up are also discussed.Lastly, we propose a simplified and universal scoring system for the reporting of fat necrosis.

Entities:  

Mesh:

Year:  2013        PMID: 23797180     DOI: 10.1007/s10549-013-2611-1

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  3 in total

1.  TOXICAN: a guide for grading dermatological adverse events of cancer treatments.

Authors:  L Peuvrel; J Cassecuel; C Bernier; G Quéreux; M Saint-Jean; M Le Moigne; C Frénard; A Khammari; B Dréno
Journal:  Support Care Cancer       Date:  2018-03-12       Impact factor: 3.603

2.  Fat necrosis in the Breast: A systematic review of clinical.

Authors:  Narges Vasei; Azita Shishegar; Forouzan Ghalkhani; Mohammad Darvishi
Journal:  Lipids Health Dis       Date:  2019-06-11       Impact factor: 3.876

3.  Volume replacement with diced acellular dermal matrix in oncoplastic breast-conserving surgery: a prospective single-center experience.

Authors:  Hongki Gwak; Ye-Won Jeon; Seung-Taek Lim; Seon-Young Park; Young-Jin Suh
Journal:  World J Surg Oncol       Date:  2020-03-24       Impact factor: 2.754

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.